openPR Logo
Press release

Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Competitive Industry Analysis, Business Strategies 2025: Johnson & Johnson, Bayer, Roche, Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Amgen, Kite Pharma, Gilead Sciences

11-28-2018 02:49 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market

Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market

Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market report is a comprehensive study in the market it tells about what the market status in the forecast period of 2018-2025. This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimate forecast frame. It helps in imagining the arrangement of the Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market complete analysis regarding type and applications, featuring the key business resources and key players. Both established and new players in the industry can use this report for complete understanding of the market. Recognize the most recent Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment improvements, share, and systems utilized by the significant market.

Get sample copy of report @

Market Drivers

• Increased public awareness of Non-Hodgkin’s Lymphoma and the drugs already in the pipeline is one of the major factors currently driving this market forward

• Increasing cases of cancer, and chronic diseases are also one of the major drivers of this market
• Improved healthcare services available in the major regions of the world would also be one of the major drivers

Non-Hodgkin’s Lymphoma is a type of cancer that attacks the lymphoma tic cells that are present in our immune system and fights off infection and diseases. It is commonly found in both adults and children, and these type of cancerous cells can be found anywhere throughout the body, as the lymphoma tic cells are spread throughout the body.

Market Restraints

• Rising cost treatment and drugs still yet to be approved by the specific authorities would prove to be a major road-block in its progress

• Chemotherapy’s side effects are also set to halt any major growth in the sector

Market Segmentation:

By treatment, all of the segments related to various treatments available in the market are set to witness worldwide growth due to the increasing cancer cases and no particular viable proven drug in the market. Global lymphoma treatment is set to witness healthy growth in all treatment segments.

By Cell Type
• B-Cell Lymphomas
• T-Cell Lymphomas

By geography, North America has been dominating the Non-Hodgkin’s Lymphoma treatment market due to its frequency of cancer cases, and it is set to continue that trend for the foreseeable future, followed by the APAC region of the world where it has developed better healthcare services and infrastructure.

Competitive Analysis:

Extensive R&D currently being conducted throughout the major pharmaceutical firms finding a treatment for Non-Hodgkin’s Lymphoma, but due to the high amount of R&D cost, it is proving to be a major hurdle in trying to find a viable solution and treatment.

Research Methodology:

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

Any specific requirements are you looking for? Ask to your Industry Experts @

Non-Hodgkin’s Lymphoma (NHL), has been expected to reach a new landscape in the forecast period due to the constant innovation and improvements on finding a viable drug to battle this disease. Due to the inability of major pharmaceuticals companies having a viable solution to it, the cost of treatment is very high and hence, the market is expected to soar higher in the forecast period of 2018-2025.

Key Developments in the Market:

• In August 2017,Gilead Sciences, Inc. and Kite Pharma, Inc. entered into a definitive agreement in August,2017 where the drug developed by Kite Pharma, Inc. currently under review by the US FDA, and is set to be one of the first drugs to be marketed for Non-Hodgkin’s Lymphoma

• In November 2017,US FDA approved a drug called Calquence by AstraZeneca, plc and will hit the market for an aggressive form of Non-Hodgkin’s Lymphoma in adults

Top Competitors:

• Hoffman-La Roche Ltd.,
• Johnson & Johnson,
• Bayer AG,
• Eli Lilly and Company,
• Amgen Inc.,
• Novartis AG,
• Bristol-Myers-Squibb,
• Gilead,
• Kite Pharma. Inc.,
• GlaxoSmithKline plc.,
• Celgene Corporation,

And Others Companies are Merck & Co., AstraZeneca, Pharmacyclics LLC, Nordic Nanovector ASA, Accredo Health Group Inc., Baxter, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Rescue Therapeutics Inc., 4SC AG, Agios Inc., Aileron Therapeutics Inc., Allinky Biopharma SL, Immune Design, are few of the major competitors currently dominating the market.

Browse Detailed TOC, Tables and Figures @

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Competitive Industry Analysis, Business Strategies 2025: Johnson & Johnson, Bayer, Roche, Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Amgen, Kite Pharma, Gilead Sciences here

News-ID: 1405534 • Views: 383

More Releases from Data Bridge Market Research

Topical Corticosteroids Market 2019 Analysis: LEO, Almirall, S.A, Bausch Health, …
The research study performed in Global Topical Corticosteroids Market report also helps to understand the various drivers and restraints impacting the market during the forecast period. The data and information have been derived from the reliable sources and include websites, annual reports of the companies, journals, and mergers which have been again checked and validated by the market experts. This market research report serves a great purpose of better decision
Global Trade Management Market is Growing | Amber Road, Inc. , Aptean, The Desca …
Global Trade Management Market research report delivers the systematic and comprehensive market research study, along with the facts and figures associated with any subject in the field of marketing. This report has a lot of features to offer about ICT industry such as the general market conditions, trends, inclinations, key players, opportunities, and geographical analysis. These and such other parameters help to take the business towards the escalation and success.
Global Depression Screening Market Report Huge Growth by 2026: F. Hoffmann-La Ro …
Global Depression Screening Market report encompasses historic data, present market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry. The forecast, analysis and estimations that are carried out in this report are all based upon the finest and well established tools and techniques such as SWOT analysis and Porter’s Five Forces analysis. The report also measures market drivers, market restraints, challenges, opportunities and key
Global Customer Success Platforms Market 2019 Business Analysis: Gainsight, Sale …
Global Customer Success Platforms Market report is one of the most significant, unique, and creditable market research reports formed by focusing on specific business prerequisites. A team of industry experts, brilliant researchers, innovative forecasters and knowledgeable analysts work with full devotion to provide clients with the qualitative market research. Even the unambiguous research studies are performed keenly to present an excellent market research report for a specific niche. Breakdown and

All 5 Releases

More Releases for Lymphoma

Lymphoma Drugs Market Growth 2019-2024
According to 24 Market Reports study, over the next five years the Lymphoma Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Burkitt Lymphoma Therapeutics Market Key Growth Drivers
Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Lymphoma Therapeutics Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Lymphoma Therapeutics Market Report 2017" Access Full Report With Table Of Contents @ In this report, the United States Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. T-Cell Lymphoma Market Analysis 2. Mechanism of T-Cell Lymphoma Therapeutics 3. T-Cell Lymphoma Drug Market Overview 3.1 Current Market Scenario 3.2 T Cell Lymphoma Clinical Pipeline Overview 4. T-Cell Lymphoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. T-Cell Lymphoma Drug Market Future Prospects 6. T-Cell Lymphoma Drug Clinical Pipeline By Company